LOwer Maintenance Dose TICagrelor in Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention

Exclusion Criteria

• •Treatment with other investigational agents (including placebo) or devices within 30 days prior to randomization or planned use of investigational agents or devices prior to the Day 30 visit.
• •Patients cannot use ticagrelor or clopidogrel due to contraindications or other reasons.
• •Patients with active pathological hemorrhage or a history of intracranial hemorrhage
• •Patient unable to receive 12 months of dual anti-platelet therapy
• •Patient developing procedure-related complications such as stent thrombosis, coronary dissection, coronary perforation, cardiac tamponade or no-reflow during PCI
• •Patient or physician refusal to enroll in the study
• •History of intracranial hemorrhage
• •Patient has a history of bleeding diathesis or coagulopathy
• •Patient has an active pathological bleeding, such as active gastrointestinal (GI) bleeding
• •Patient is pregnant, breastfeeding, or planning to become pregnant within 12 months
• •Patient is receiving chronic oral anticoagulation therapy (i.e., vitamin K antagonist, direct thrombin inhibitor, Factor Xa inhibitor)
• •Patient with cardiogenic shock or mechanical circulatory assist devices placed
• •Patient with active liver diseases
• •Patient with severe renal insufficiency (eGFR \<30ml/min/1.73m2 based on simplified MDRD equation or CrCl \<30ml/min based on Cockcroft-Gault equation)
• •Patient has a malignancy or a life expectancy of less than one year
• •Platelet count \<100 000/μL, or hematocrit \<32% or \>52%, or white blood cell count \<3000/μL
• •Any other condition deemed by the investigator to place the patient at excessive risk of bleeding with ticagrelor